**Sir,**

Our goal when this study was designed was to understand whether the findings of the initial study ([@bib2]) could also be useful at other clinical time points, and whether neutrophil-to-lymphocyte ratio (NLR) retained independent significance when established clinical prognostic factors were incorporated. The data did not support our initial hypothesis, and the correspondents take issue with this ([@bib3]). The validation of prognostic markers in retrospective series frequently generates conflicting findings, and we all await a robustly designed prospective study to resolve this controversy.

The correspondents suggest that our study was flawed due to the inclusion criteria that they considered were arbitrarily defined and that led to selection bias. We acknowledge that this is an inherent limitation of all retrospective studies, including previous studies of the NLR. In the initial study ([@bib2]), only patients receiving systemic therapy were selected, and 61% were selected due to their participation in clinical trials. Subsequent studies selected only patients undergoing extrapleural pneumonectomy (EPP) ([@bib1]) or only patients with occupational dust exposure seeking compensation from the Dust Disease Board ([@bib4]). In a fourth study, patients were excluded if they had a history of inflammatory disease, a second primary, active infection or insufficient follow-up data ([@bib5]). These were therefore also studies with heterogeneous patient populations receiving different treatment approaches.

We set out to validate NLR at diagnosis and at the time of starting treatment, using pre-specified selection criteria and therefore screened all consecutive patients where: (a) the disease under study was confirmed, (b) the variable under study was available and (c) there were no co-existing confounders that may influence the disease or variable under study. It would not be possible to validate the prognostic significance of NLR in patients where the target biomarker was unknown, and we therefore maintain the appropriateness of our selection criteria, and have transparently reported the study denominator. Moreover, all other missing data were described in our report, and the resulting multivariate model was the first published NLR study to include previously established clinical and laboratory prognostic variables. Our data were analysed using rigorous statistical methodology, including the consideration of missing data by multiple imputation.

Kao *et al* maintain that our data showed 'unusually good overall survival\', and this can be adequately refuted by referring to our paper, where we defined overall survival (OS) as being calculated from the time of diagnosis, but also provided OS from the time of commencement of systemic therapy. This was 12.3 months for all patients receiving chemotherapy and 11.7 months for those treated with chemotherapy only (that is, non-surgically). This OS does not differ materially from an OS of 12.1 months for the intervention arm of the landmark cisplatin/pemetrexed study ([@bib6]) and an OS of 11.7 months for the chemotherapy-naive group of the initial study of NLR in MPM ([@bib2]).

The results were indeed not what we had originally anticipated; nevertheless, we have pursued the scientifically and ethically appropriate course of reporting 'negative\' results, which are contradictory to others\' findings. Failure to publish negative findings can lead to substantial publication bias in retrospective analyses of data. Our data were subjected to rigorous statistical methodology and we have reported what we found. Furthermore, the NLR cut-off was not data driven but selected *a priori* on the basis of the correspondents\' own published literature. In our discussion, we cautioned against data-driven cut-offs and note that the NLR literature is not consistent in choice of cut-point, which may also have resulted in contradictory findings across studies. Kao *et al* refer to other manuscripts confirming the prognostic value of NLR that were published during the period in which our manuscript was in submission and in press and that continue to inform scientific debate. At the time of submission we were not privy to these data, which may reflect either an increasing literature on the importance of NLR or alternatively a positive publication bias in retrospective series.

We acknowledge Kao *et al* as the initiators of this field in mesothelioma and, as previously stated, had anticipated confirming their initial study ([@bib2]) in an additional cohort. That we were not able to do this is not a repudiation of the potential value of NLR, but an invitation for additional rigorous prospective research in the field to fully define the place of this potential prognostic marker.
